

Study title	Time tO last ChemotherApy and death in ovaRian cancEr patients: TO CARE/MITO 42 study , a retrospective analysis of italian MITO centers.
Sponsor	SCDU Oncologia Medica, Ospedale Mauriziano, Umberto I di Torino
Principals Investigators	Giorgio Valabrega MD Giulia Scotto MD (Co-PI)
Consortium/network	MITO Group
Study design and methods	Retrospective, observational, multicenter study aimed at evaluating the time elapsed between the last chemotherapy administered and death in patients with epithelial ovarian cancer. The medical records of patients with ovarian cancer treated in MITO Centers in Italy will be analyzed
Study population	Ovarian cancer patients who underwent surgery between January 2010 and December 2020 will be selected. The following data will be retrospectively recorded: patient characteristics, histological type, FIGO stage, first line treatment, relapses and subsequent treatments, clinical data before the start of the last line of therapy, date of administration of the last chemotherapy, eventual decision to interrupt the chemotherapy and the reason, date of death.
Inclusion criteria	1) All patients diagnosed with ovarian cancer (any histotype admitted) who underwent surgery between January 2010 and December 2020 in the Participating Centers. 2) Patients who have died and whose date of death is known. 3) Patients whose date of the last chemotherapy treatment performed is known.
Exclusion criteria	1) Patients with ovarian cancer still alive 2) Patients with ovarian cancer who have died and whose date of death is not known 3) Patients with ovarian cancer whose date of the last chemotherapy is not known
Primary objective	The primary objective is to evaluate the time elapsed between the last chemotherapy administered and death in patients with ovarian cancer.

Secondary objectives	To describe the clinical features of patients receiving chemotherapy in the end of life before the start of the last line of therapy and to define any prognostic factors associated.
Duration of participation	July 2022: submission to the EC Mauriziano Hospital of Turin By December 2022: data collection